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 ABSTRACT 
 Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) 
associated malignant tumor. Recently, anti-tumor effect of cidofovir, an 
anti-viral drug to an acyclic nucleoside analogue, has been reported to have 
anti-tumor potential. Thus, two cases of NPC, who have received 
multi-round therapy, were treated with cidofovir. Cidofovir was topically 
injected in and around the tumor once per 3 weeks. Tumor growth was 
suppressed for several months around the injection site in each patient. 
EBV-encoded RNAs in situ hybrodization revealed the reduction of the 
tumor cell population, however, EBERs expression was still maintained in 
the NPC tumor cells. Although anti-tumor mechanism remains unclear, 
these results suggest that cidofovir is actually an effective and safe agent 
for the treatment of NPC.  
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INTRODUCTION 
 Chemoradiotherapy has been recognized as a standard treatment of 
fresh nasopharyngeal carcinoma (NPC). Recurrent NPC is a disease with 
poor prognosis because re-irradiation and anti-cancer chemotherapy only 
has poor response rates and raise severe morbidity rates. Moreover salvage 
surgery plays only a limited role because of its complicated anatomical 
location. Thus, treatment of locally recurrent NPC has been a matter of 
issue for several decades (1, 2). NPC is unique with contribution of 
Epstein-Barr virus (EBV), a member of Herpesvirus, to tumorigenesis and 
progression (3, 4), which suggests some treatment value of anti-viral drugs 
against NPC. Cidofovir, an acyclic nucleoside analogue, shows 
anti-proliferation effect against broad range of viral species including EBV. 
It has been reported to have anti-tumor potential. Here, we report two cases 
of NPC, who have received multi-round therapy, treated with topical 
injection of cidofovir. The protocol in this report was approved by the 
Institute Review Board of Kanazawa University Hispotal. 
 
CASE REPORT 
Case 1: A 30-year-old man was diagnosed to nasopharyngeal carcinoma 
(NPC) with T4N0M0 disease in 1998. He received cisplatin + 5FU 
neoadjuvant chemotherapy and radiotherapy at the initial treatment, 
eventually, achieved complete response. The disease recurred at the surface 
area of the nasopharynx in 2000, and the tumor was treated with 
endoscopic laser surgery and with 24Gy of brachytherapy. The treatment 
controlled the local disease for a year. MRI revealed tumor regrowth in 
deeper portion than the previously detected recurrent diseases. The tumor 
did not respond to docetaxel (80mg/m2) and then, he received 
nasopharyngectomy via maxillar-swing approach and reconstructed with 
forearm free flap. Although complete resection was confirmed in surgical 
specimen, the disease recurred at the primary site in 2003. At that time, the 
tumor was treated with topical injection of cidofovir (75mg, diluted with 
normal saline to 1:4 ) at a time, once per week, 5 times). He received one 
more series of cidofovir injection. During the treatment, successfully 
injected site of the tumor did not grow whereas unsuccessful site of the 
tumor, mainly deeper portion, gradually increased its size (Fig. 1). 
Eventually, he died of intracranial invasion in 2005. 
 
Case 2.   The second case was 63-year-old male with rT2N0M0. At the 
initial treatment, he received neoadjuvant chemotherapy (Pirarubicine 
30mg/m2 and cisplatin 70mg/m2 on day 1, pepleomycin 5mg/m2 on day 2 
to 6, 2 course, every 3 weeks) and sequential radiotherapy 52.4Gy in 1995 
at a local hospital. Five years after, he received neo adjuvant chemotherapy 
(5FU 650mg/m2 on day 1 to 5, Nedaplatine 100mg/m2 on day 6) and 
second-round radiation therapy (34 Gy, 2Gy/day, 5days/week) for the 
recurrent tumor. Six months after the treatment, the disease recurred. He 
was treated with topical injection of cidofovir (6.25 mg at a time, once per 
3 week, 5 times) in 2002. Similar to the patient 1, tumor size did not 
increase after completion of cidofovir injection for three months. Tumor 
growth stopped, however, not remarkable regression. An endoscopic 
nasopharyngectomy was undertaken for the purpose of improving nasal 
congestion and histological evaluation. There were faint tumor cells in 
submucosal area where tumor invasion was confirmed by previously biopsy. 
One year later, metastatic disease arose at the rt-parotid gland. Again, 
topical injection of cidofovir was conducted at the metastatic site. The 
tumor remained in stable size for a year (Fig. 2). However, multiple organ 
metastasis developed sequentially, and then, he has been receiving weekly 
low-dose docetaxel (25mg/m2 ) for 2 years. The metastatic tumor in the 
parotid grand began to grow again 3 months after stopping cidofovir 
injection and 6 months after suspension of cidofovir, facial palsy developed. 
Although he is at terminal disease stage, he still alive with multiple 
systemic metastasis. 
   
Histological studies 
 Effect of cidofovir angiogenesis was studied in the nasopharyngeal 
carcinoma tissues. For clear identification of EBV positive NPC tumor 
cells, the tumor tissue samples were examined by EBV-encoded RNAs 
(EBERs) in situ hybridization. It revealed that the population of EBERs 
positive tumor cell decreased 3 months after completion of cidoforvir 
injection. In contrast, proportion of stroma increased where there had been 
tumor cells. Suggesting anti-tumor effect of cidofovir. There was no 
EBERs negative tumor cells in the post-cidofovir treatment samples, 
suggesting that cidofovir had not been working to eradicate EBV.  (Fig. 
3). 
        
 
DISCUSSION 
 Cidofovir belongs to the acyclic nucleoside phosphonate analogues, 
which is characterized by a stable phosphonate linkage between the acyclic 
nucleoside and the phosphate moiety. Thus, cidofovir possesses distinct 
feature to antiviral drugs such as acyclovir and ganciclovir, in that it 
bypasses the first phosphorylation step by herpesvirus-encoded kinases (5). 
 NPC is an EBV-associated malignant disease in which EBV is 
latently infected (3). In addition to the fact that NPC, as well as HPV 
papillomatosis, is an epithelial tumor caused by an oncogenic DNA virus, 
recent successful report of cidofovir for EBV-associated disease in athymic 
nude mice model rendered us to use this drug for the treatment of recurrent 
human NPC (6, 7). Two drug delivery systems, intravenous and topical 
injection, have been clinically used for cidofovir administration against 
human disease. Intravenous injection is recommended for the treatment of 
CMV retinitis in AIDS patients, and topical injection has been successful 
for laryngeal papillomatosis (5, 8). Based on three reasons, topical injection 
was selected for both patients. The first one is the similarity of laryngeal 
papillomatosis with NPC in that these diseases are epithelial neoplasms. 
Next one is that intravenous dose was not effective against Kaposi sarcoma 
(9).  The third one is less nephrotoxicity of topical use. The patients 
reported here had received CDDP-based full dose chemotherapy, major 
side effect of which is nephrotoxicity. Nephrotoxicity is also a major side 
effect of cidofovir.  
 The deeper portion of tumor such as intracranial invasion site did 
not seem that cidofovir had been delivered in case 1, however, topical 
cidofovir injection turned out to be both physically and pathologically 
effective treatment for topical deliverable portion. Moreover, topically 
delivered cidofovir controlled parotid gland metastasis for one year. 
Histological evaluation of the metastatic site was not performed to avoid 
facial nerve palsy in case 2. Thus, we cannot tell if there were viable tumor 
cells or not. However, it is obvious that the treatment was clinically quite 
benefitial for the patients as either progression of the disease in the parotid 
gland or tumor resection would have been caused facial palsy.  
 An approach against EBV-associated tumor has been attempted in 
the way to induce viral lytic replication. Short-chain fatty acids, such as 
butyrate, induce EBV-Thymidine kinase (TK) expression in latently 
infected B cells. The combination of arginine butyrate and ganciclovir was 
reasonably well-tolerated and appears to have significant biologic activity 
in vivo in EBV-infected lymphoid malignancies which are refractory to 
other regimens (10). Theoretically, cidofovir does not require an induction 
of viral lytic replication. Thus, induction of EBV-TK expression by 
butyrate is not essential for cidofovir treatment.  
 It is not possible to be conclusive if anti-tumor effect for these NPC 
tumors is virus dependent or not so far. EBERs are abundantly transcribed 
in the latently infected EBV positive cells but not in such cells where viral 
is replicating. Expression of EBERs in the residual tumor cell seems 
similar although population of tumor cell itself diminished. Serum 
EBV-DNA copy-number, as well as intensity of EBERs staining, did not 
change before and after cidofovir treatment in each case.  These results 
suggest that cidofovir did not act to eradicate latently infected EBV in 
human NPC. Anti-tumor mechanism of cidofovir for NPC as well as 
papillomatosis has not been elucidated yet. While the anti-viral effects of 
cidofovir can be attributed to the interaction of diphosphorylated-cidofovir 
with the viral DNA polymerase and incorporation of cidofovir into the viral 
DNA chain, its specific inhibitory activity against the proliferation of 
HPV-infected cells must imply additional or alternative mechanism of 
action. The anti-proliferative effect of cidofovir on the growth of 
HPV-infected cells, akin to its inhibitory effect on the growth of NPC, may 
be ascribed the induction of apoptosis (11). This, in turn, may be related to 
the ability of cidofovir to restore the function of the tumor suppressor 
protein p53 in EBV-infected cells. Interestingly, inhibitory effect of 
cidofovir against non-viral transformed tumor cells via suppression of 
angiogenesis has been reported. The dormant attitude of NPC tumor in the 
two cases may partly be due to this anti-angiogenic effect of cidofovir (12).  
 The results presented here suggest that cidofovir treatment can be 
an alternative modality for the patients with recurrent nasopharyngeal 
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 Figure legends 
Figure 1: MRI of the cidofovir injected site in case 1.  
(A) Before starting cidofovir injection to the NPC invaded to the left nasal 
cavity.  
(B) Four weeks after completion of a series of cidofovir injection. Nasal 
obstruction was improved after cidofovir treatment. Maxillary sinus 
empyema also improved along with the shrinkage of the nasal tumor 
(white arrowhead).  
Arrows in the figures indicate injection site of cidofovir.  
 
Figure 2: MRI of the cidofovir injected site in and 2 
(A) Before starting cidofovir injection to the metastasized NPC at the 
patorid gland. 
(B) Three months after completion of a series of cidofovir injection. 
Tumor size remained stable before and after cidofovir treatment. 
Arrowheads indicate the metastatic tumor. 
 
Figure 3: Pathological analysis of EBV positive NPC before and after 
cidofovir treatment in case 1. (In situ hybridization for EBERs). 
(A) Before starting cidofovir treatment. 
(B) Four week after completion a series of cidofovir treatment. 
Tumor cells are identified with dark blue EBERs staining signals (arrow). 
 
  
